These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32432777)

  • 1. A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis.
    Yamanaka M; Iwata H; Masuda K; Araki M; Okuno Y; Okamura M; Koiwa J; Tanaka T
    Eur Rev Med Pharmacol Sci; 2020 May; 24(9):5127-5139. PubMed ID: 32432777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
    Yin J; Mobarec JC; Kolb P; Rosenbaum DM
    Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia].
    Tanaka Y; Aoki I; Ishine T; Renger JJ; Winrow CJ; Hisada S
    Nihon Yakurigaku Zasshi; 2016 Jul; 148(1):46-56. PubMed ID: 27430679
    [No Abstract]   [Full Text] [Related]  

  • 4. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
    Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
    Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
    Prajapati SK; Krishnamurthy S
    Behav Brain Res; 2021 Feb; 399():113015. PubMed ID: 33212086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA.
    Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T
    Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
    Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
    ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
    Brotschi C; Bolli MH; Gatfield J; Heidmann B; Jenck F; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
    ChemMedChem; 2020 Mar; 15(5):430-448. PubMed ID: 31945272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of suvorexant.
    Stahl SM
    CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Suvorexant, a Dual Orexin/Hypocretin Receptor Antagonist, on Impulsive Behavior Associated with Cocaine.
    Gentile TA; Simmons SJ; Watson MN; Connelly KL; Brailoiu E; Zhang Y; Muschamp JW
    Neuropsychopharmacology; 2018 Apr; 43(5):1001-1009. PubMed ID: 28741623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for orexinergic mechanisms in migraine.
    Hoffmann J; Supronsinchai W; Akerman S; Andreou AP; Winrow CJ; Renger J; Hargreaves R; Goadsby PJ
    Neurobiol Dis; 2015 Feb; 74():137-43. PubMed ID: 25447225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suvorexant as an orexin antagonist may regulate serum glucose levels in psychiatric patients with insomnia.
    Nakamura M; Nagamine T
    Psychiatry Clin Neurosci; 2017 Dec; 71(12):844. PubMed ID: 28945327
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats.
    Steiner MA; Toeroek-Schafroth M; Dacome L; Tessari M
    J Psychopharmacol; 2023 Dec; 37(12):1261-1264. PubMed ID: 37982383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation.
    Hong C; Byrne NJ; Zamlynny B; Tummala S; Xiao L; Shipman JM; Partridge AT; Minnick C; Breslin MJ; Rudd MT; Stachel SJ; Rada VL; Kern JC; Armacost KA; Hollingsworth SA; O'Brien JA; Hall DL; McDonald TP; Strickland C; Brooun A; Soisson SM; Hollenstein K
    Nat Commun; 2021 Feb; 12(1):815. PubMed ID: 33547286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
    Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
    J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
    Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enantioselective synthesis of a dual orexin receptor antagonist.
    Mangion IK; Sherry BD; Yin J; Fleitz FJ
    Org Lett; 2012 Jul; 14(13):3458-61. PubMed ID: 22725839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.